EP2049135A4 - Lactoferrin as a radioprotective agent - Google Patents

Lactoferrin as a radioprotective agent

Info

Publication number
EP2049135A4
EP2049135A4 EP07784522A EP07784522A EP2049135A4 EP 2049135 A4 EP2049135 A4 EP 2049135A4 EP 07784522 A EP07784522 A EP 07784522A EP 07784522 A EP07784522 A EP 07784522A EP 2049135 A4 EP2049135 A4 EP 2049135A4
Authority
EP
European Patent Office
Prior art keywords
lactoferrin
radioprotective agent
radioprotective
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP07784522A
Other languages
German (de)
French (fr)
Other versions
EP2049135A2 (en
Inventor
Atul Varadhachary
Karel Petrak
Paul Blezinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agennix Inc
Original Assignee
Agennix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agennix Inc filed Critical Agennix Inc
Publication of EP2049135A2 publication Critical patent/EP2049135A2/en
Publication of EP2049135A4 publication Critical patent/EP2049135A4/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
EP07784522A 2006-06-22 2007-06-22 Lactoferrin as a radioprotective agent Ceased EP2049135A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80554006P 2006-06-22 2006-06-22
PCT/US2007/071942 WO2007150049A2 (en) 2006-06-22 2007-06-22 Lactoferrin as a radioprotective agent

Publications (2)

Publication Number Publication Date
EP2049135A2 EP2049135A2 (en) 2009-04-22
EP2049135A4 true EP2049135A4 (en) 2009-12-30

Family

ID=38834430

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07784522A Ceased EP2049135A4 (en) 2006-06-22 2007-06-22 Lactoferrin as a radioprotective agent

Country Status (4)

Country Link
EP (1) EP2049135A4 (en)
CN (1) CN101505781A (en)
CA (1) CA2655331A1 (en)
WO (1) WO2007150049A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201304041D0 (en) * 2013-03-06 2013-04-17 Water Jel Europ Llp Treatment and prophylaxis of radiation dermatitis
CN111671885A (en) * 2020-06-15 2020-09-18 中国人民解放军西部战区总医院 Medicine for treating radiodermatitis
CN111514280A (en) * 2020-06-15 2020-08-11 中国人民解放军西部战区总医院 Medicine for preventing radiodermatitis

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645589B2 (en) * 1990-07-13 1994-01-20 Novozymes Biopharma Dk A/S Growth-promoting agent
WO1996034614A1 (en) * 1995-05-02 1996-11-07 Gropep Pty. Ltd. Method of preventing or treating alimentary tract damage due to chemotherapy or radiation
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
WO2002092077A2 (en) * 2001-05-16 2002-11-21 N.V. Nutricia Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
WO2004060081A1 (en) * 2003-01-07 2004-07-22 N.V. Nutricia A method of improving nutrient utilisation by a mammal and a composition for use therein
US20040214750A1 (en) * 2003-04-28 2004-10-28 Georgiades Izolda M. Medicaments for healing skin conditions in humans
RU2005119153A (en) * 2005-06-21 2006-12-27 Федеральное государственное унитарное предпри тиеГосударственный научный центр - Институт биофизики Федерального медико-биологического агентства (RU) MEANS OF TREATMENT OF ACUTE RADIATING DISEASE

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571697A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
US5571691A (en) 1989-05-05 1996-11-05 Baylor College Of Medicine Production of recombinant lactoferrin and lactoferrin polypeptides using CDNA sequences in various organisms
DK0590060T3 (en) 1991-06-21 1998-05-11 Univ Cincinnati Orally administrable therapeutic proteins and method of preparation
ZA932568B (en) 1992-04-24 1993-11-12 Baylor College Midecine A Non Production of recombinant human lactoferrin
AU6307698A (en) 1997-02-03 1998-08-25 Pharming Bv Useful properties of human lactoferrin and variants thereof
US20030203839A1 (en) * 1999-10-29 2003-10-30 Kruzel Marian L. Immune enhancing composition containing lactoferrin
WO2006047744A2 (en) * 2004-10-26 2006-05-04 Agennix Incorporated Compositions of lactoferrin related peptides and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU645589B2 (en) * 1990-07-13 1994-01-20 Novozymes Biopharma Dk A/S Growth-promoting agent
WO1996034614A1 (en) * 1995-05-02 1996-11-07 Gropep Pty. Ltd. Method of preventing or treating alimentary tract damage due to chemotherapy or radiation
WO2001024812A1 (en) * 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
WO2002092077A2 (en) * 2001-05-16 2002-11-21 N.V. Nutricia Use of lipoic acid for suppressing undesired haematological effects of chemotherapy and/or radiotherapy
WO2004060081A1 (en) * 2003-01-07 2004-07-22 N.V. Nutricia A method of improving nutrient utilisation by a mammal and a composition for use therein
US20040214750A1 (en) * 2003-04-28 2004-10-28 Georgiades Izolda M. Medicaments for healing skin conditions in humans
RU2005119153A (en) * 2005-06-21 2006-12-27 Федеральное государственное унитарное предпри тиеГосударственный научный центр - Институт биофизики Федерального медико-биологического агентства (RU) MEANS OF TREATMENT OF ACUTE RADIATING DISEASE

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ARTYM J ET AL: "Reconstitution of the cellular immune response by lactoferrin in cyclophosphamide-treated mice is correlated with renewal of T cell compartment", IMMUNOBIOLOGY, URBAN UND FISCHER VERLAG, DE, vol. 207, no. 3, 1 January 2003 (2003-01-01), pages 197 - 205, XP004954075, ISSN: 0171-2985, DOI: 10.1078/0171-2985-00233 *
BELINDA VAN'T LAND ET AL: "Lactoferrin Reduces Methotrexate-Induced Small Intestinal Damage, Possibly Through Inhibition of GLP-2-Mediated Epithelial Cell Proliferation", DIGESTIVE DISEASES AND SCIENCES, vol. 49, no. 3, 1 March 2004 (2004-03-01), pages 425 - 433, XP055010171, ISSN: 0163-2116, DOI: 10.1023/B:DDAS.0000020497.35250.93 *
BELJAARS L ET AL: "Inhibition of cytomegalovirus infection by lactoferrin in vitro and in vivo", ANTIVIRAL RESEARCH, ELSEVIER SCIENCE BV., AMSTERDAM, NL, vol. 63, no. 3, 1 September 2004 (2004-09-01), pages 197 - 208, XP004579999, ISSN: 0166-3542 *
FUJIHARA T ET AL: "Lactoferrin protects against UV-B irradiation-induced corneal epithelial damage in rats.", CORNEA MAR 2000, vol. 19, no. 2, March 2000 (2000-03-01), pages 207 - 211, XP008115199, ISSN: 0277-3740 *
J. ARTYM ET AL: "Lactoferrin Accelerates Reconstitution of the Humoral and Cellular Immune Response During Chemotherapy-induced Immunosuppression and Bone Marrow Transplant in Mice", STEM CELLS AND DEVELOPMENT, vol. 14, no. 5, 1 October 2005 (2005-10-01), pages 548 - 555, XP055008464, ISSN: 1547-3287, DOI: 10.1089/scd.2005.14.548 *
PIET DIRIX ET AL: "Efficacy of the BioXtra dry mouth care system in the treatment of radiotherapy-induced xerostomia", SUPPORTIVE CARE IN CANCER, SPRINGER-VERLAG, DE, vol. 15, no. 12, 18 January 2007 (2007-01-18), pages 1429 - 1436, XP019564647, ISSN: 1433-7339 *
See also references of WO2007150049A2 *
SUSUMU TERAGUCHI ET AL: "Protection against infections by oral lactoferrin: Evaluation in animal models", BIOMETALS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 17, no. 3, 1 June 2004 (2004-06-01), pages 231 - 234, XP019232200, ISSN: 1572-8773, DOI: 10.1023/B:BIOM.0000027697.83706.32 *
TERESA G HAYES ET AL: "Phase I trial of oral talactoferrin alfa in refractory solid tumors", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, vol. 24, no. 3, 20 September 2005 (2005-09-20), pages 233 - 240, XP019394384, ISSN: 1573-0646 *
VARADHACHARY ATUL ET AL: "Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 111, no. 3, 1 September 2004 (2004-09-01), pages 398 - 403, XP002538536, ISSN: 0020-7136, [retrieved on 20040423], DOI: 10.1002/IJC20271 *

Also Published As

Publication number Publication date
EP2049135A2 (en) 2009-04-22
CN101505781A (en) 2009-08-12
CA2655331A1 (en) 2007-12-27
WO2007150049A2 (en) 2007-12-27
WO2007150049A3 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
DK3165539T3 (en) Il-17-receptor a antigenbindende proteiner
EP2023449A4 (en) Connecting member
IL180020A0 (en) Encryption -and decryption-enabled interfaces
ZA200706592B (en) Gripper
EP2065801A4 (en) Emulator
EP2062892A4 (en) Hypertension-ameliorating agent
GB0624587D0 (en) Chelating agent
AP2008004724A0 (en) Substituted1-yl)-azolin-2-aryl-1-hetaryl-ethane
EP2030629A4 (en) Lipid-metabolism-improving agent
EP2083114A4 (en) Fiber product-treating agent
HK1171661A1 (en) Agent utilizing helipyrone a helipyrone a
EP2060263A4 (en) Lipid-metabolism-ameliorating agent
EP2049135A4 (en) Lactoferrin as a radioprotective agent
GB0607223D0 (en) Abutment member
GB0713585D0 (en) Equivalent
EP1849358A4 (en) Rodenticide agent
GB2440449B (en) A soakaway
HK1112992A1 (en) Manipulator
GB0617794D0 (en) A nemometer
GB0625861D0 (en) Modified flexicast/flexisplint
DE502007001126D1 (en) Eiten
EP2057992A4 (en) Renal-function-ameliorating agent
GB2429022B (en) Abutment member
TWI319058B (en) Connecting member
AU3514P (en) ARCBENT Arctotis fastuosa

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: BLEZINGER, PAUL

Inventor name: PETRAK, KAREL

Inventor name: VARADHACHARY, ATUL

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20091202

17Q First examination report despatched

Effective date: 20100330

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120610